Welcome to our dedicated page for Immuneering SEC filings (Ticker: IMRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Immuneering's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Immuneering's regulatory disclosures and financial reporting.
Immuneering Corporation reported fourth-quarter and full-year 2025 results alongside major clinical progress for its lead cancer drug candidate, atebimetinib. In an ongoing Phase 2a trial in first-line pancreatic cancer, atebimetinib plus mGnP showed 64% overall survival at 12 months, compared with a 35% standard-of-care benchmark for GnP.
The company finished 2025 with $217 million in cash, cash equivalents and marketable securities and expects its cash runway to extend into 2029. Fourth-quarter 2025 research and development expenses fell to $9.3 million from $14.9 million a year earlier, while general and administrative expenses rose to $4.5 million. Net loss narrowed to $11.6 million, or $0.18 per share, from $18.1 million, or $0.58 per share.
Immuneering plans to start dosing in its pivotal Phase 3 MAPKeeper 301 trial in first-line metastatic pancreatic cancer in mid-2026 and initiate a Phase 2 lung cancer trial of atebimetinib plus Libtayo in the second half of 2026.
Immuneering Corp’s chief legal officer and secretary, Michael Bookman, received a new stock option grant. On February 3, 2026, he was awarded options to purchase 176,000 shares of Class A common stock at an exercise price of $4.91 per share.
The options vest in equal monthly installments over four years starting February 1, 2026, and will be fully vested and exercisable on January 1, 2030. All 176,000 derivative securities are reported as directly owned following this grant.
Immuneering Corp reported that its Chief Business Officer, Harold Eugene Brakewood, received a stock option award covering 140,000 shares of Class A common stock on February 3, 2026. The option has an exercise price of $4.91 per share and is held directly.
The option vests in equal monthly installments over four years, beginning on February 1, 2026, and will be fully vested and exercisable on January 1, 2030. After this grant, Brakewood beneficially owns 140,000 derivative securities linked to Immuneering’s Class A common stock.
Immuneering Corp's chief scientific officer, Brett Matthew Hall, reported a new stock option grant. On February 3, 2026, he was awarded options to purchase 344,000 shares of Class A common stock at an exercise price of $4.91 per share.
The options vest in equal monthly installments over four years, starting February 1, 2026, and are scheduled to be fully vested and exercisable on January 1, 2030. After this grant, Hall beneficially owns 344,000 stock options, all held directly.
Immuneering Corp’s Chief Medical Officer, Igor Matushansky, received a new stock option grant. On February 3, 2026, he was awarded options to acquire 140,000 shares of Class A common stock at an exercise price of $4.91 per share.
The options vest in equal monthly installments over four years starting February 1, 2026 and are scheduled to be fully vested and exercisable on January 1, 2030, aligning long-term compensation with the company’s future performance.
Immuneering Corp executive Mallory Morales, SVP Finance and Chief Accounting Officer, received a grant of stock options covering 140,000 shares of Class A common stock on February 3, 2026. The options have an exercise price of $4.91 per share and were granted at no cost.
The option award vests in equal monthly installments over four years starting February 1, 2026 and will be fully vested and exercisable on January 1, 2030. Following this grant, Morales beneficially owns 140,000 stock options directly.
Immuneering Corp’s chief people officer receives new stock options grant. Leah R. Neufeld was awarded stock options covering 140,000 shares of Class A common stock on February 3, 2026, with an exercise price of $4.91 per share and no purchase price for the options themselves.
The options vest in equal monthly installments over four years starting February 1, 2026, and are scheduled to be fully vested and exercisable on January 1, 2030. Following this grant, Neufeld beneficially owns 140,000 derivative securities directly through this option award.
Immuneering Corp reported that President and CEO Benjamin J. Zeskind received a grant of stock options on February 3, 2026. The award covers 688,000 options with an exercise price of $4.91 per share, each option linked to Class A common stock.
According to the filing, the options vest in equal monthly installments over four years starting on February 1, 2026, and will be fully vested and exercisable by January 1, 2030. Following this grant, Zeskind beneficially owns 688,000 derivative securities directly.
Benjamin J. Zeskind reports beneficial ownership of 4,357,807 shares of Immuneering Corporation Class A common stock, representing 6.6% of the class. This ownership is calculated as of December 31, 2025, based on 64,569,967 shares outstanding as of November 5, 2025, as disclosed in Immuneering’s Form 10-Q. The position includes 2,312,852 shares held directly, 1,150,028 shares underlying stock options exercisable on or before March 1, 2026, and 894,927 shares held by the Benjamin J. Zeskind 2020 Family Trust, for which his spouse is sole trustee. Zeskind has sole voting and dispositive power over 3,462,880 shares and shared voting and dispositive power over 894,927 shares.
Immuneering Corp’s Chief Business Officer, Harold Eugene Brakewood, reported buying Class A common stock. On January 16, 2026, he purchased 5,250 shares of Immuneering’s Class A common stock at a price of $4.76 per share, coded as an open-market or private purchase (transaction code "P").
After this transaction, Brakewood beneficially owned a total of 11,050 shares of Immuneering Class A common stock, held in direct ownership.